Question · asked by 1 review
Teriparatide 20 microg daily in addition to standard care vs placebo + standard care: Healing of MRONJ
- Population
- People with established (manifest) MRONJ
- Intervention
- Teriparatide 20 microg daily in addition to standard care
- Comparison
- placebo + standard care
- Outcome
- Healing of MRONJ
Teriparatide 20 microg daily in addition to standard care showed no clear difference in healing of MRONJ (resolution of lesions) compared with placebo in addition to standard care (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Teriparatide 20 microg daily in addition to standard care vs Placebo in addition to standard care Healing of MRONJ (resolution of lesions) · People with established (manifest) MRONJ · 52 weeks Teriparatide 20 microg daily in addition to standard care showed no clear difference in healing of MRONJ (resolution of lesions) compared with placebo in addition to standard care (low certainty). Interventions for managing medication‐related osteonecrosis of the jaw (2022) · Cochrane All outcomes | RR 0.96 [0.31, 2.95] | 1 study · 33 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for managing medication‐related osteonecrosis of the jaw 2022 · Cochrane All outcomes | 2021-06 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.